Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION) (H-54744)
Description
Content
The purpose of this study is to find out how safe and effective the new drug, AMX0035, is for the treatment of PSP and to determine if AMX0035 can slow down disease progression.
AMX0035 is an oral medication (taken by mouth). Its use in this study is considered investigational, which means that is has not yet been approved by the U.S. Food and Drug Administration (FDA) for treatment of PSP. This study will provide more information on AMX0035.
Contact
Phone 1: 713–798–5989
IRB: H-54744
Status:
Active
Created:
